These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2465 related articles for article (PubMed ID: 9403702)

  • 1. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
    Rak J; Mitsuhashi Y; Bayko L; Filmus J; Shirasawa S; Sasazuki T; Kerbel RS
    Cancer Res; 1995 Oct; 55(20):4575-80. PubMed ID: 7553632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
    Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
    Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.
    Yen L; Benlimame N; Nie ZR; Xiao D; Wang T; Al Moustafa AE; Esumi H; Milanini J; Hynes NE; Pages G; Alaoui-Jamali MA
    Mol Biol Cell; 2002 Nov; 13(11):4029-44. PubMed ID: 12429844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
    Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody.
    Crombet-Ramos T; Rak J; Pérez R; Viloria-Petit A
    Int J Cancer; 2002 Oct; 101(6):567-75. PubMed ID: 12237899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.
    Riedel F; Götte K; Li M; Hörmann K; Grandis JR
    Int J Oncol; 2002 Jul; 21(1):11-6. PubMed ID: 12063543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
    Maity A; Pore N; Lee J; Solomon D; O'Rourke DM
    Cancer Res; 2000 Oct; 60(20):5879-86. PubMed ID: 11059786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
    Pal S; Datta K; Mukhopadhyay D
    Cancer Res; 2001 Sep; 61(18):6952-7. PubMed ID: 11559575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
    Yuan F; Chen Y; Dellian M; Safabakhsh N; Ferrara N; Jain RK
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14765-70. PubMed ID: 8962129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 124.